Older Women: Some Painkillers May Raise Heart Risk
Class of drugs that includes naproxen linked to increased chance of heart attack, stroke, but finding not conclusive
By Dennis Thompson
TUESDAY, July 8, 2014 (HealthDay News) -- A category of painkillers that includes the popular over-the-counter drug naproxen (Aleve) might increase an older woman's risk of heart attack or stroke, researchers report.
Doctors already knew that nonsteroidal anti-inflammatory drugs (NSAIDs) that target and inhibit the so-called "cox-2 enzyme" can raise a person's heart attack risk.
This new study found the same sort of heart risks accompany NSAIDs that don't specifically target cox-2, but still inhibit the enzyme to some degree.
That category of NSAIDs was associated with a 17 percent increase in postmenopausal women's risk of heart attack or stroke, compared to a 13 percent increase associated with NSAIDs that specifically target and inhibit cox-2.
"These are widely used drugs in this country and worldwide, so it has huge ramifications," said study author Dr. Anthony Bavry, an associate professor of cardiovascular medicine with the University of Florida's College of Medicine, in Gainesville. "Naproxen, which inhibits cox-2 more than cox-1, was associated with a 22 percent increased risk of death, heart attack or stroke," he said.
NSAIDs work by influencing cyclooxygenase (cox), an enzyme that helps regulate inflammation in the body. The enzyme comes in two forms, cox-1 and cox-2. Cox-1 helps protect the lining of the stomach and tends to promote blood clots, while cox-2 is found in the lining of blood vessels and works to prevent blood clots, Bavry explained.
Prior research has found that specifically inhibiting cox-2 can increase heart attack and stroke risk, so much so that two NSAIDs that targeted cox-2 -- Vioxx and Bextra -- were pulled from the market for safety reasons in the mid-2000s.
Bavry and his colleagues decided to test whether any NSAID that tends to inhibit cox-2 would create the same health risk, even if the drug doesn't specifically target cox-2.
The finding already has sparked some controversy, with current American Heart Association President Dr. Elliott Antman calling the findings against naproxen an "overreach."
"The totality of the evidence still leaves us comfortable recommending naproxen as a medication that can be used for a short period at a lower dose for people with risk of heart disease," Antman said.